North America Drug Delivery Devices Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2024 –2031 |
 Taille du marché (année de référence) |
USD 788.49 Billion |
 Taille du marché (année de prévision) |
USD 1,351.11 Billion |
 TCAC |
% |
| Principaux acteurs du marché |
|
>Marché des dispositifs d'administration de médicaments en Amérique du Nord, par type de produit ( administration de médicaments par voie orale , administration de médicaments par voie injectable, administration de médicaments topiques, administration de médicaments ophtalmiques, administration de médicaments par voie nasaleadministration de médicaments par voie pulmonaire , administration de médicaments par voie transmuqueuse et administration de médicaments implantables ), utilisateur final (hôpitaux, soins de santé à domicile, cliniques, soins de santé communautaires et autres), canal de distribution (appels d'offres directs, pharmacies hospitalières, pharmacies et pharmacies en ligne) - Tendances et prévisions de l'industrie jusqu'en 2031.
Analyse et taille du marché des dispositifs d'administration de médicaments en Amérique du Nord
Le marché nord-américain des dispositifs d'administration de médicaments connaît une croissance importante, tirée par la prévalence croissante des maladies chroniques et non chroniques, la croissance du développement des dispositifs de médicaments biologiques et la sensibilisation croissante au diagnostic et au traitement. Le marché est caractérisé par la présence d'un grand nombre d'acteurs proposant une large gamme de dispositifs de diagnostic adaptés aux divers besoins des prestataires de soins de santé de la région.
Data Bridge Market Research analyse que le marché nord-américain des dispositifs d'administration de médicaments croît avec un TCAC de 7,3 % au cours de la période de prévision de 2024 à 2031 et devrait atteindre 1 351,11 milliards USD d'ici 2031 contre 788,49 milliards USD en 2023.
|
Rapport métrique |
Détails |
|
Période de prévision |
2024 à 2031 |
|
Année de base |
2023 |
|
Année historique |
2022 (Personnalisable 2016-2021) |
|
Unités quantitatives |
Chiffre d'affaires en milliards USD |
|
Segments couverts |
Type de produit (administration orale de médicaments, administration injectable de médicaments, administration topique de médicaments, administration ophtalmique de médicaments, administration nasale de médicaments, administration pulmonaire de médicaments , administration transmuqueuse de médicaments et administration implantable de médicaments), utilisateur final (hôpitaux, soins de santé à domicile, cliniques, soins de santé communautaires et autres), canal de distribution (appels d'offres directs, pharmacies hospitalières, pharmacies et pharmacies en ligne) |
|
Pays couverts |
États-Unis, Canada et Mexique |
|
Acteurs du marché couverts |
BD, F. Hoffmann-La Roche Ltd, Novartis AG, Sanofi, Johnson & Johnson Services, Inc., 3M, Gerresheimer AG, Medmix, OraSure Technologies Inc., Enable Injection, Insulet Corporation, Bayer AG, Pfizer Inc., GSK plc., Merck & Co., Inc., Amgen Inc., AbbVie Inc., Elcam Medical, SMC Ltd., ViVO Smart Medical Devices Ltd., West et Pharmaceutical Services, Inc. entre autres |
Définition du marché
Drug delivery devices are medical devices designed to deliver medications to the body in a controlled and targeted manner, enhancing their efficacy, safety, and patient compliance. These devices can be external, such as inhalers, injectors, and pumps, or internal such as implantable devices, and are used to administer a wide range of medications, including small molecules, biologics, and vaccines. They can modify the release rate, bioavailability, and absorption of drugs, as well as provide real-time monitoring and feedback to patients and healthcare providers. Drug delivery devices play a crucial role in optimizing treatment outcomes and improving patient quality of life for various diseases and conditions, including chronic conditions, infectious diseases, and cancer.
North America Drug Delivery Devices Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail as below:
Drivers
- Rising Prevalence of Chronic Disease and Non-Chronic Disease
The prevalence of diseases and conditions such as Cardiovascular Diseases (CVDs), asthma, cancer, neurological disorders, stroke, diabetes, and respiratory diseases has increased significantly over some time. Mentioned below are some of the important statistics related to some of the chronic diseases. The rising prevalence of chronic and non-chronic diseases significantly influences the growth of the drug delivery devices market. Chronic diseases such as diabetes, cardiovascular diseases, and respiratory disorders are becoming more widespread, necessitating long-term treatment plans that require efficient and reliable drug delivery device methods.
- Growth in the Development of Biologics Drugs Devices
Biologics is considered one of the fastest-growing segments in the pharmaceutical market. Development and manufacturing of biologics for both branded and generic drugs is becoming increasingly competitive with the presence of players. Biologics are generally administered through injections in the arms, legs or abdomen. For instance, Cimzia, Cosentyx, Enbrel, and Humira among others.
Opportunity
- Rising Acceptance of Self-Administering Drug Devices
Self-administration of drugs by the patients is expected to provide significant growth opportunities for drug delivery players focusing on the development of innovative and new devices. Major factors contributing to this are growing elderly population, as aged population forms large consumer base for homecare drug delivery devices. Pharmaceutical companies are focusing on the development of patient-friendly therapies and self-administered drug-device combination products. With the increasing acceptance of self-administration, the need for application-specific injection, inhalation, topical, and transdermal drug products is also increasing.
Restraint/Challenge
- Side Effects of Drug Delivery Systems
Adverse reactions to drug delivery systems can lead to a decrease in patient compliance, which can result in decreased demand for the device. This can negatively impact the sales and revenue of the device manufacturer. Side effects can raise concerns about patient safety, leading to increased scrutiny and regulation from regulatory agencies. This can lead to delays in product launches, additional testing requirements, and increased costs for device manufacturers. Moreover, side effects can lead to device rejection by patients, resulting in a decrease in demand for the device. This can be particularly problematic for devices that require long-term use, such as implantable devices.
Recent Developments
- In August 2023, Janssen Pharmaceutical Companies of Johnson & Johnson Services, Inc. submitted the supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking sanction of DARZALEX in combination with Kyprolis and dexamethasone for relapsed/refractory multiple myeloma. If approved this will increase the product portfolio and also revenue generation of the company
- In January 2020, Janssen Pharmaceutical Companies of Johnson & Johnson Services, Inc. announced that EC has given the grant to market Erleada which is used to treat metastatic hormone-sensitive prostate cancer (mHSPC) in combination with Androgen Deprivation Therapy (ADT). This will increase their market presence which will further increase the revenue generation
- In December 2020, Janssen Pharmaceutical Companies of Johnson & Johnson Services, Inc. announced the EC approval of SPRAVATO nasal spray, which will enhance their product portfolio which will further increase the revenue
North America Drug Delivery Devices Market Scope
The North America drug delivery devices market is segmented into three notable segments based on product type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Product Type
- Oral Drug Delivery
- Injectable Drug Delivery
- Topical Drug Delivery
- Ophthalmic Drug Delivery
- Nasal Drug Delivery
- Pulmonary Drug Delivery
- Transmucosal Drug Delivery
- Implantable Drug Delivery
On the basis of product type, the North America drug delivery devices market is segmented into injectable drug delivery formulations, injectable drug delivery, topical drug delivery, ophthalmic drug delivery, nasal drug delivery, pulmonary drug delivery, transmucosal drug delivery, and implantable drug delivery.
End User
- Hospitals
- Home Healthcare
- Clinics
- Community Healthcare
- Others
On the basis of end user, the North America drug delivery devices market is segmented into hospitals, home healthcare, clinics, community healthcare and others.
Distribution Channel
- Direct Tenders
- Hospital Pharmacies
- Pharmacy Stores
- Online Pharmacy
Sur la base du canal de distribution, le marché nord-américain des dispositifs d'administration de médicaments est segmenté en appels d'offres directs, pharmacies hospitalières, pharmacies et pharmacies en ligne.
Analyse/perspectives régionales du marché des dispositifs d'administration de médicaments en Amérique du Nord
Le marché nord-américain des dispositifs d’administration de médicaments est analysé et des informations et tendances sur la taille du marché sont fournies en fonction du type de produit, de l’utilisateur final et du canal de distribution, comme référencé ci-dessus.
Les pays couverts dans ce rapport de marché sont les États-Unis, le Canada et le Mexique.
L’Amérique du Nord devrait dominer le marché en raison de facteurs tels que son infrastructure de soins de santé avancée, ses investissements élevés en R&D et sa forte demande de technologies médicales innovantes.
Les États-Unis devraient dominer le marché nord-américain en raison de leur infrastructure de soins de santé avancée, de leurs investissements importants dans la recherche et le développement et d’un cadre réglementaire solide qui soutient l’innovation.
La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements dans la réglementation du marché qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques et l'analyse des cinq forces du porteur, les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte tout en fournissant une analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché des dispositifs d'administration de médicaments en Amérique du Nord
Le marché nord-américain des dispositifs d'administration de médicaments est segmenté en trois segments notables en fonction du type de produit, de l'utilisateur final et du canal de distribution.
Le paysage concurrentiel du marché des dispositifs d'administration de médicaments en Amérique du Nord fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises sur le marché des dispositifs d'administration de médicaments en Amérique du Nord.
Certains des principaux acteurs opérant sur le marché des dispositifs d'administration de médicaments en Amérique du Nord sont BD, F. Hoffmann-La Roche Ltd, Novartis AG, Sanofi, Johnson & Johnson Services, Inc., 3M, Gerresheimer AG, Medmix, OraSure Technologies Inc., Enable Injection, Insulet Corporation, Bayer AG, Pfizer Inc., GSK plc., Merck & Co., Inc., Amgen Inc., AbbVie Inc., Elcam Medical, SMC Ltd., ViVO Smart Medical Devices Ltd., West et Pharmaceutical Services, Inc. entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA DRUG DELIVERY DEVICES MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 PRODUCT TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTERS FIVE FORCES
4.2 PESTEL ANALYSIS
5 REGULATORY FRAMEWORK
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF CHRONIC DISEASE AND NON-CHRONIC DISEASE
6.1.2 GROWTH IN THE DEVELOPMENT OF BIOLOGICS DRUGS DEVICES
6.1.3 INCREASING AWARENESS ABOUT DIAGNOSIS AND TREATMENT
6.1.4 INCREASED FOCUS ON PERSONALIZED MEDICINE AND DEVICES
6.2 RESTRAINTS
6.2.1 RISK OF NEEDLE-STICK INJURIES AND SIDE EFFECTS
6.2.2 HIGH COSTS OF INJECTABLE DRUGS
6.2.3 STRINGENT REGULATORY SCENARIO
6.3 OPPORTUNITIES
6.3.1 RISING ACCEPTANCE OF SELF-ADMINISTERING DRUG DEVICES
6.3.2 RISING DEMAND FOR BIOSIMILAR AND GENERIC DRUGS
6.3.3 THERAPEUTIC ADVANCEMENTS IN THE FIELD OF DRUG DELIVERY
6.4 CHALLENGES
6.4.1 SIDE EFFECTS OF DRUG DELIVERY SYSTEMS
6.4.2 INCREASE IN THE NUMBER OF ALTERNATIVES OF DRUG DELIVERY
7 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 ORAL DRUG DELIVERY
7.2.1 SOLID ORAL DRUGS
7.2.1.1 TABLETS
7.2.1.2 CAPSULES
7.2.1.3 PILLS
7.2.1.4 POWDERS
7.2.2 LIQUID ORAL DRUGS
7.2.2.1 SYRUPS
7.2.2.2 SOLUTIONS
7.2.3 SEMI SOLID ORAL DRUGS
7.2.3.1 GELS
7.2.3.2 EMULSIONS
7.2.3.3 ELIXIRS
7.3 INJECTABLE DRUG DELIVERY
7.3.1 INJECTABLE DRUG DELIVERY FORMULATIONS
7.3.1.1 CONVENTIONAL DRUG DELIVERY FORMULATIONS
7.3.1.2 NOVEL DRUG DELIVERY FORMULATIONS
7.3.1.3 LONG ACTING INJECTION FORMULATIONS
7.3.2 INJECTABLE DRUG DELIVERY DEVICES
7.3.2.1 CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES
7.3.2.1.1 BY MATERIAL
7.3.2.1.1.1 GLASS
7.3.2.1.1.2 PLASTIC
7.3.2.1.2 BY PRODUCT TYPE
7.3.2.1.2.1 FILLABLE
7.3.2.1.2.2 PRE-FILLED
7.3.2.1.3 BY USABILITY
7.3.2.1.3.1 REUSABLE SYRINGES
7.3.2.1.3.2 DISPOSABLE SYRINGES
7.3.2.2 SELF INJECTION DRUG DELIVERY DEVICES
7.3.2.2.1 NEEDLE FREE INJECTORS
7.3.2.2.2 WEARABLE INJECTORS
7.3.2.2.3 PEN INJECTOR
7.3.2.2.4 AUTO INJECTORS
7.3.2.2.5 OTHERS
7.4 TOPICAL DRUG DELIVERY
7.4.1 TRANSDERMAL DRUG DELIVERY FORMULATIONS
7.4.1.1 SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS
7.4.1.1.1 OINTMENTS
7.4.1.1.2 CREAMS
7.4.1.1.3 LOTIONS
7.4.1.1.4 GELS
7.4.1.1.5 PASTES
7.4.1.2 LIQUID TOPICAL DRUG DELIVERY FORMULATIONS
7.4.1.2.1 SUSPENSIONS
7.4.1.2.2 SOLUTIONS
7.4.1.3 SOLID TOPICAL DRUG DELIVERY FORMULATIONS
7.4.1.3.1 POWDER
7.4.1.3.2 SUPPOSITORS
7.5 OPHTHALMIC DRUG DELIVERY
7.5.1 OCCULAR DRUG DELIVERY FORMULATIONS
7.5.1.1 LIQUID OCCULAR DRUG DELIVERY FORMULATIONS
7.5.1.1.1 SOLUTIONS
7.5.1.1.2 SUSPENSIONS
7.5.1.2 SEMI SOLID OCCULAR DRUG DELIVERY FORMULATIONS
7.5.1.2.1 GELS
7.5.1.2.2 OINTMENTS
7.5.2 OCCULAR DRUG DELIVERY DEVICES
7.6 NASAL DRUG DELIVERY
7.6.1 NASAL DROPS
7.6.2 NASAL SPRAYS
7.6.3 NASAL POWDERS
7.6.4 NASAL GELS
7.7 PULMONARY DRUG DELIVERY
7.7.1 METERED DOSE INHALERS (MDI)
7.7.2 DRY POWDER INHALERS (DPI)
7.7.3 NEBULIZERS
7.7.3.1 JET NEBULIZERS
7.7.3.2 ULTRASONIC NEBULIZERS
7.7.3.3 SOFT MIST NEBULIZERS
7.8 TRANSMUCOSAL DRUG DELIVERY
7.8.1 ORAL TRANSMUCOSAL DRUG DELIVERY
7.8.1.1 BUCCAL DRUG DELIVERY
7.8.1.2 SUBLINGUAL DRUG DELIVERY
7.8.2 OTHER TRANSMUCOSAL DRUG DELIVERY
7.8.2.1 RECTAL TRANSMUCOSAL DRUG DELIVERY
7.8.2.2 VAGINAL TRANSMUCOSAL DRUG DELIVERY
7.9 IMPLANTABLE DRUG DELIVERY
7.9.1 PASSIVE IMPLANTABLE DRUG DELIVERY DEVICES
7.9.2 ACTIVE IMPLANTABLE DRUG DELIVERY DEVICES
8 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY END USER
8.1 OVERVIEW
8.2 HOSPITALS
8.3 HOME HEALTHCARE
8.4 CLINICS
8.5 COMMUNITY HEALTHCARE
8.6 OTHERS
9 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 DIRECT TENDERS
9.3 HOSPITAL PHARMACIES
9.4 PHARMACY STORES
9.5 ONLINE PHARMACY
10 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY REGION
10.1 NORTH AMERICA
10.1.1 U.S.
10.1.2 CANADA
10.1.3 MEXICO
11 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: COMPANY LANDSCAPE
11.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
12 SWOT ANALYSIS
13 COMPANY PROFILE
13.1 JOHNSON & JOHNSON SERVICES, INC.
13.1.1 COMPANY SNAPSHOT
13.1.2 REVENUE ANALYSIS
13.1.3 COMPANY SHARE ANALYSIS
13.1.4 PRODUCT PORTFOLIO
13.1.5 RECENT DEVELOPMENTS
13.2 NOVARTIS AG
13.2.1 COMPANY SNAPSHOT
13.2.2 REVENUE ANALYSIS
13.2.3 COMPANY SHARE ANALYSIS
13.2.4 PRODUCT PORTFOLIO
13.2.5 RECENT DEVELOPMENTS
13.3 F. HOFFMANN-LA ROCHE LTD
13.3.1 COMPANY SNAPSHOT
13.3.2 REVENUE ANALYSIS
13.3.3 COMPANY SHARE ANALYSIS
13.3.4 PRODUCT PORTFOLIO
13.3.5 RECENT DEVELOPMENT
13.4 BAYER AG
13.4.1 COMPANY SNAPSHOT
13.4.2 REVENUE ANALYSIS
13.4.3 COMPANY SHARE ANALYSIS
13.4.4 PRODUCT PORTFOLIO
13.5 PFIZER INC.
13.5.1 COMPANY SNAPSHOT
13.5.2 REVENUE ANALYSIS
13.5.3 COMPANY SHARE ANALYSIS
13.5.4 PRODUCT PORTFOLIO
13.5.5 RECENT DEVELOPMENT
13.6 3M
13.6.1 COMPANY SNAPSHOT
13.6.2 REVENUE ANALYSIS
13.6.3 PRODUCT PORTFOLIO
13.6.4 RECENT DEVELOPMENTS
13.7 ABBVIE INC.
13.7.1 COMPANY SNAPSHOT
13.7.2 REVENUE ANALYSIS
13.7.3 PRODUCT PORTFOLIO
13.7.4 RECENT DEVELOPMENTS
13.8 AMGEN INC.
13.8.1 COMPANY SNAPSHOT
13.8.2 REVENUE ANALYSIS
13.8.3 PRODUCT PORTFOLIO
13.8.4 RECENT DEVELOPMENTS
13.9 BD
13.9.1 COMPANY SNAPSHOT
13.9.2 REVENUE ANALYSIS
13.9.3 PRODUCT PORTFOLIO
13.9.4 RECENT DEVELOPMENT
13.1 ELCAM MEDICAL
13.10.1 COMPANY SNAPSHOT
13.10.2 PRODUCT PORTFOLIO
13.10.3 RECENT DEVELOPMENT
13.11 ENABLE INJECTIONS
13.11.1 COMPANY SNAPSHOT
13.11.2 PRODUCT PORTFOLIO
13.11.3 RECENT DEVELOPMENTS
13.12 GERRESHEIMER AG
13.12.1 COMPANY SNAPSHOT
13.12.2 REVENUE ANALYSIS
13.12.3 PRODUCT PORTFOLIO
13.12.4 RECENT DEVELOPMENTS
13.13 GSK PLC.
13.13.1 COMPANY SNAPSHOT
13.13.2 REVENUE ANALYSIS
13.13.3 PRODUCT PORTFOLIO
13.13.4 RECENT DEVELOPMENTS
13.14 INSULET CORPORATION
13.14.1 COMPANY SNAPSHOT
13.14.2 REVENUE ANALYSIS
13.14.3 PRODUCT PORTFOLIO
13.14.4 RECENT DEVELOPMENTS
13.15 MEDMIX
13.15.1 COMPANY SNAPSHOT
13.15.2 REVENUE ANALYSIS
13.15.3 PRODUCT PORTFOLIO
13.15.4 RECENT DEVELOPMENTS
13.16 MERCK & CO., INC.
13.16.1 COMPANY SNAPSHOT
13.16.2 REVENUE ANALYSIS
13.16.3 PRODUCT PORTFOLIO
13.16.4 RECENT DEVELOPMENT
13.17 ORASURE TECHNOLOGIES INC.
13.17.1 COMPANY SNAPSHOT
13.17.2 REVENUE ANALYSIS
13.17.3 PRODUCT PORTFOLIO
13.17.4 RECENT DEVELOPMENT
13.18 SANOFI
13.18.1 COMPANY SNAPSHOT
13.18.2 REVENUE ANALYSIS
13.18.3 PRODUCT PORTFOLIO
13.18.4 RECENT DEVELOPMENTS
13.19 SMC LTD.
13.19.1 COMPANY SNAPSHOT
13.19.2 REVENUE ANALYSIS
13.19.3 PRODUCT PORTFOLIO
13.19.4 RECENT DEVELOPMENTS
13.2 VIVO SMART MEDICAL DEVICES LTD.
13.20.1 COMPANY SNAPSHOT
13.20.2 PRODUCT PORTFOLIO
13.20.3 RECENT DEVELOPMENT
13.21 WEST PHARMACEUTICAL SERVICES, INC.
13.21.1 COMPANY SNAPSHOT
13.21.2 REVENUE ANALYSIS
13.21.3 PRODUCT PORTFOLIO
13.21.4 RECENT DEVELOPMENT
14 QUESTIONNAIRE
15 RELATED REPORTS
Liste des tableaux
TABLE 1 LIST OF FDA APPROVED BIOLOGICS, IN 2022
TABLE 2 10 MOST EXPENSIVE DRUGS IN THE U.S. (IN USD MILLION)
TABLE 3 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 4 NORTH AMERICA ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 5 NORTH AMERICA ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 6 NORTH AMERICA SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 7 NORTH AMERICA LIQUID ORAL DRUG IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 8 NORTH AMERICA SEMI SOLID ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 9 NORTH AMERICA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 10 NORTH AMERICA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 11 NORTH AMERICA INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 12 NORTH AMERICA INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 13 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)
TABLE 14 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE 2022-2031 (USD MILLION)
TABLE 15 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 16 NORTH AMERICA SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 17 NORTH AMERICA TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 18 NORTH AMERICA TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 19 NORTH AMERICA TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 20 NORTH AMERICA SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 21 NORTH AMERICA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 22 NORTH AMERICA SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 23 NORTH AMERICA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 24 NORTH AMERICA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 25 NORTH AMERICA OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 26 NORTH AMERICA LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 27 NORTH AMERICA SEMI SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 28 NORTH AMERICA NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 29 NORTH AMERICA NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 30 NORTH AMERICA PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 31 NORTH AMERICA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 32 NORTH AMERICA NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 33 NORTH AMERICA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 34 NORTH AMERICA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 35 NORTH AMERICA ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 36 NORTH AMERICA OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 37 NORTH AMERICA IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 38 NORTH AMERICA TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 39 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 40 NORTH AMERICA HOSPITALS IN DRUG DELIVERY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 41 NORTH AMERICA HOME HEALTHCARE IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 42 NORTH AMERICA CLINICS IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 43 NORTH AMERICA COMMUNITY HEALTHCARE IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 44 NORTH AMERICA OTHERS IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 45 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 46 NORTH AMERICA DIRECT TENDERS IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 47 NORTH AMERICA HOSPITAL PHARMACIES IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 48 NORTH AMERICA PHARMACY STORES IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 49 NORTH AMERICA ONLINE PHARMACY IN DRUG DELIVERY DEVICES MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 50 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 51 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 52 NORTH AMERICA ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 53 NORTH AMERICA SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 54 NORTH AMERICA LIQUID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 55 NORTH AMERICA SEMI SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 56 NORTH AMERICA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 57 NORTH AMERICA INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 58 NORTH AMERICA INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 59 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)
TABLE 60 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 61 NORTH AMERICA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 62 NORTH AMERICA SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 63 NORTH AMERICA TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 64 NORTH AMERICA TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 65 NORTH AMERICA SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 66 NORTH AMERICA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 67 NORTH AMERICA SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 68 NORTH AMERICA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 69 NORTH AMERICA OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 70 NORTH AMERICA LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 71 NORTH AMERICA SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 72 NORTH AMERICA NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 73 NORTH AMERICA PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 74 NORTH AMERICA NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 75 NORTH AMERICA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 76 NORTH AMERICA ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 77 NORTH AMERICA OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 78 NORTH AMERICA IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 79 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 80 NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 81 U.S. DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 82 U.S. ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 83 U.S. SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 84 U.S. LIQUID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 85 U.S. SEMI SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 86 U.S. INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 87 U.S. INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 88 U.S. INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 89 U.S. CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)
TABLE 90 U.S. CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 91 U.S. CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 92 U.S. SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 93 U.S. TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 94 U.S. TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 95 U.S. SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 96 U.S. LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 97 U.S. SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 98 U.S. OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 99 U.S. OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 100 U.S. LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 101 U.S. SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 102 U.S. NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 103 U.S. PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 104 U.S. NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 105 U.S. TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 106 U.S. ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 107 U.S. OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 108 U.S. IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 109 U.S. DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 110 U.S. DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 111 CANADA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 112 CANADA ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 113 CANADA SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 114 CANADA LIQUID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 115 CANADA SEMI SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 116 CANADA INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 117 CANADA INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 118 CANADA INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 119 CANADA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)
TABLE 120 CANADA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 121 CANADA CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 122 CANADA SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 123 CANADA TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 124 CANADA TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 125 CANADA SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 126 CANADA LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 127 CANADA SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 128 CANADA OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 129 CANADA OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 130 CANADA LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 131 CANADA SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 132 CANADA NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 133 CANADA PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 134 CANADA NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 135 CANADA TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 136 CANADA ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 137 CANADA OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 138 CANADA IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 139 CANADA DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 140 CANADA DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 141 MEXICO DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 142 MEXICO ORAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 143 MEXICO SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 144 MEXICO LIQUID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 145 MEXICO SEMI SOLID ORAL DRUGS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 146 MEXICO INJECTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 147 MEXICO INJECTABLE DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 148 MEXICO INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 149 MEXICO CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY MATERIAL, 2022-2031 (USD MILLION)
TABLE 150 MEXICO CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 151 MEXICO CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 152 MEXICO SELF INJECTION DRUG DELIVERY DEVICES IN DRUG DELIVERY DEVICES MARKET, BY USABILITY, 2022-2031 (USD MILLION)
TABLE 153 MEXICO TOPICAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 154 MEXICO TRANSDERMAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 155 MEXICO SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 156 MEXICO LIQUID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 157 MEXICO SOLID TOPICAL DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 158 MEXICO OPHTHALMIC DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 159 MEXICO OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY FORM, 2022-2031 (USD MILLION)
TABLE 160 MEXICO LIQUID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 161 MEXICO SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS IN DRUG DELIVERY DEVICES MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 162 MEXICO NASAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 163 MEXICO PULMONARY DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 164 MEXICO NEBULIZERS IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 165 MEXICO TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 166 MEXICO ORAL TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 167 MEXICO OTHER TRANSMUCOSAL DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 168 MEXICO IMPLANTABLE DRUG DELIVERY IN DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 169 MEXICO DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 170 MEXICO DRUG DELIVERY DEVICES MARKET, BY END USER, 2022-2031 (USD MILLION)
Liste des figures
FIGURE 1 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: SEGMENTATION
FIGURE 11 EXECUTIVE SUMMARY
FIGURE 12 EIGHT SEGMENTS COMPRISE THE NORTH AMERICA DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE
FIGURE 13 STRATEGIC DECISIONS
FIGURE 14 RISING PREVALENCE OF CHRONIC DISEASE AND NON-CHRONIC DISEASE ARE DRIVING THE GROWTH OF THE NORTH AMERICA DRUG DELIVERY DEVICES MARKET FROM 2024 TO 2031
FIGURE 15 THE ORAL DRUG DELIVERY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA DRUG DELIVERY DEVICES MARKET IN 2024 AND 2031
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA DRUG DELIVERY DEVICES MARKET
FIGURE 17 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY PRODUCT TYPE, 2023
FIGURE 18 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY PRODUCT TYPE, 2023-2031 (USD MILLION)
FIGURE 19 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY PRODUCT TYPE, CAGR (2024-2031)
FIGURE 20 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 21 NORTH AMERICA DRUG DELIVERY MARKET: BY END USER, 2023
FIGURE 22 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 23 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: END USER, CAGR (2024-2031)
FIGURE 24 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: END USER, LIFELINE CURVE
FIGURE 25 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 26 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 27 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 28 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 29 NORTH AMERICA DRUG DELIVERY DEVICES MARKET: COMPANY SHARE 2023 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
